Answers are grounded in this paper and cite their sources.
Dust exposures are observed in some production departments of pharmaceutical industries, especially in tablet manufacturing processes. This dust generally includes a portion of therapeutic material. The development of an adequate industrial hygiene monitoring strategy is therefore required to evaluate these specific exposures. The first step for a proper health risk assessment consists of establishing adequate exposure limits for each drug of interest. Second, the dust must be sampled to quantify the drug exposure. This monitoring often requires the development of analytical methods for each pharmaceutical active of concern. However, the development of analytical methods for some drugs is a procedure too expensive for many industries, especially where industrial hygiene resources are limited. These difficulties would be avoided if the proportion of drug in the total dust could be estimated without direct chemical analysis of the drug. Over a three-year period, two types of granulation processes were monitored in one pharmaceutical industry. Total dust exposure levels and drug ratios in the recipe were compared with drug exposures obtained with direct drug analysis. The data suggest that a direct comparison was possible between total dust air sampling results and drug concentrations, depending on the manufacturing process used. Tartre, A.: An Industrial Hygiene Monitoring Strategy for Dust in the Pharmaceutical Industry. Appl. Occup. Environ. Hyg. 7(11):764–771; 1992.
No takes yet. Share an insight, caveat, or question.
Andre Tartre (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: